Japan Delays Keytruda Pricing Amid PD-1 Cost Concerns
Regulatory authorities in Japan have put back the granting of a reimbursement price to Keytruda under the national health insurance system amid rising worries over the cost of new cancer immunotherapies, delaying the launch of the product for now.
You may also be interested in...
Merck’s Keytruda could see its launch price set lower too after Opdivo’s rapidly rising use in lung cancer triggers maximum statutory price cut.
China continues to be the brightest star in AstraZeneca's emerging markets firmament amid some "softness" in other countries, and the UK group sees attractive prospects in the country for some of its innovative branded products.
Sharply rising medical spending in Japan, driven in part by expensive new drugs, is now attracting attention at the highest political levels, with a key prime ministerial council set to debate potential cost-cutting measures.